AndhraNews.net
Home » Features » Health » Prostate cancer

Prostate cancer


About Prostate cancer

Prostate cancer is a type of cancer that develops in the prostate. Prostate is a gland in the male reproductive system. Prostate Cancer is generally slow growing, but in some cases aggressive growth is also witnessed.

It is the second most common cause of cancer among men in the United States, behind Skin cancer. Only 10 per cent of men diagnosed with prostate cancer die from it.

Scientists have warned that a gender-bending chemical found in babies' bottles may raise the odds of getting prostate cancer in later life.

Prostate Cancer Statistics

A study by University of Haifa showed that countries with the highest level of Nighttime artificial lighting have the highest rates of prostate cancer cases.

Prostate Cancer Detection

Another study shows that men who develop prostate cancer face an increased risk of having an aggressive tumour if they carry a so-called breast cancer gene mutation. Men who are very sexually active in their 20s and 30s run a higher risk of prostate cancer.

Studies in 2008 showed that a simple non-invasive biomarker test (urine test) beats PSA in detecting prostate cancer. British and Australian scientists found seven new sites in the human genome that are linked to a man's risk of developing prostate cancer.

Obesity in men may hide early evidence of prostate cancer as the condition lowers prostate-specific antigen levels, also known as PSA values.

Treatment for Prostate Cancer

According to studies and research, various drugs, vaccines or things that might slow down prostate cancer include Chemotherapy drugs, certain type of Measles virus, herbal supplements, blocking signaling proteins, 100% pomegranate juice, walnut etc.

The cancer is slow-moving and often it requires no treatment other than regular monitoring.

Radiation Therapy

When the cancer is localized to prostate and hasn't spread to other parts of the body, radiation therapy is a standard treatment. The radiation can be applied either externally or internally. External radiation is through beams directed at the cancerous area, while internal radiation is through radioactive seeds the size of rice that are implanted in the prostate.

Radiation Therapy is typically given between five to nine weeks.

The side effects are minor and patients are expected to feel some fatigue.

Sonablate High Intensity Focused Ultrasound (HIFU)

Sonablate HIFU on initial use is very patient friendly for those who are suffering from carcinoma prostate as there is no immediate morbidity which is expected if the patient chooses radical surgery. The long term side effects are also reduced since the treatment is done by sound waves rather than radiation. The treatment is most convenient as the patient is admitted only for one day and, since there is no blood loss during procedure, can return to work very quickly.

Sonablate HIFU in India

The first Sonablate HIFU services in India were performed by Dr. Ramesh Ramayya at Dr. Ramayya's Pramila Urology Hospital in Hyderabad in December 2008. The second location in India to offer HIFU as a minimally invasive treatment for prostate cancer was Primus Super Specialty Hospital in New Delhi in March 2009. Rajiv Gandhi Cancer Institute & Research Centre (RGCI & RC), New Delhi began offering Sonablate HIFU services from July 17, 2009.

Celebrities and Prominent People diagnosed with Prostate cancer

Prostate cancer in News

Bavarian Nordic Enters Licensing and Collaboration Agreement with Janssen for MVA-BN® in the Development of a Therapeutic HPV Vaccine

OncBioMune Selected to Present at Biotech Showcase 2016
BATON ROUGE, LA--(Marketwired - December 16, 2015) - OncBioMune Pharmaceuticals, Inc

Medigene AG: Promising data from Phase I/II IIT and Compassionate Use Programme with dendritic cell vaccines in AML presented at ASH Annual Meeting 2015
Medigene AG /Medigene AG: Promising data from Phase I/II IIT and Compassionate Use Programme with dendritic cell vaccines in AML presented at ASH Annual Meeting 2015 . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Molecular Diagnostics Market Worth $9.50 Billion by 2022: Grand View Research, Inc.
The global molecular diagnostics market is expected to reach over USD 9.50 billion by 2022, according to a new report by Grand View Research Inc. Growing prevalence of chronic diseases and infections such as HPV and influenza is anticipated to be the key driver for molecular diagnostics market growth

This #GivingTuesday Donate to the Movember Foundation and Change the Face of Men's Health
LOS ANGELES, CA--(Marketwired - December 01, 2015) - The Movember Foundation, one of the largest global men's health charities investing in programs to address prostate cancer, testicular cancer, poor mental health and physical inactivity, is putting out a call for final donations at Movember.com this #GivingTuesday

Nanobiotix's Soft Tissue Sarcoma pivotal trial expands dynamically as planned: already 7 countries and 29 sites opened

Medtronic Sponsors the Addario Lung Cancer Foundation's "Simply the Best" Dinner and Gala
SAN CARLOS, CA--(Marketwired - November 12, 2015) - The Bonnie J. Addario Lung Cancer Foundation (ALCF) today announced Medtronic as a title sponsor for its tenth annual "Simply the Best" Dinner and Gala. Through the sponsorship, Medtronic is demonstrating its commitment to reduce lung cancer morbidity by improving early diagnosis, thereby leading to earlier, personalized treatment

OncBioMune Receives Notice of Patent Allowance for Cancer Vaccine ProscaVax(TM) in China and Ukraine
BATON ROUGE, LA--(Marketwired - November 10, 2015) - OncBioMune Pharmaceuticals, Inc

IsoRay Reports First Quarter Fiscal 2016 Financial Results
RICHLAND, WA--(Marketwired - November 10, 2015) - IsoRay, Inc

Bristol-Myers Squibb Sponsors the Addario Lung Cancer Foundation's "Simply the Best" Dinner and Gala
SAN CARLOS, CA--(Marketwired - November 10, 2015) - The Bonnie J. Addario Lung Cancer Foundation (ALCF) today announced Bristol-Myers Squibb (BMS) as a title sponsor for its tenth annual "Simply the Best" Dinner and Gala

BioCancell Advances Intellectual Property Portfolio in the United States
BioCancell Ltd. (TASE: BICL), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies to treat cancer-related diseases, today announced that the U.S. Patent and Trademark Office has approved a patent for BioCancell's second-generation drug, BC-821

Bavarian Nordic Announces Results of a Phase 1 Trial Investigating Brachyury Specific Cancer Vaccine in Patients with Advanced Cancers
Novel Vaccine Induced Brachyury Specific T-cells in ~80% of Patients at Higher Dose Levels COPENHAGEN, Denmark, November 3, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today results from an NCI-sponsored Phase 1 study investigating its novel cancer vaccine, MVA-BN® Brachyury

MD Anderson's Moon Shots Mission Grows to Confront Six More Cancer Types
HOUSTON, TX--(Marketwired - October 30, 2015) - MD Anderson's Moon Shots Program, an unprecedented effort and novel organizational model designed to more rapidly convert scientific discoveries into life-saving advances, has expanded its targets, adding several of the most intractable cancers to its campaign.

Bavarian Nordic Announces Expansion of IMVAMUNE® Orders from Canadian Government
COPENHAGEN, Denmark, October 28, 2015 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that the Public Health Agency of Canada (PHAC) has ordered 143,000 doses of IMVAMUNE® (liquid-frozen formulation), a non-replicating smallpox vaccine. This order, valued at USD 6

Bavarian Nordic to Host Third Quarter 2015 Results Conference Call
COPENHAGEN, Denmark - October 27, 2015 - Bavarian Nordic A/S (OMX:BAVA, OTC: BVNRY) will announce its 2015 third quarter results on Tuesday, November 3, 2015.

Barbershops Across the U.S. Shave the Date for Movember 2015
LOS ANGELES, CA--(Marketwired - October 27, 2015) - In just five days, the official Movember 2015 campaign will launch with "Shave the Date," the day men all over the world will start clean shaven and begin growing spectacular moustaches to raise awareness and funds for men's health issues

Orion Group Interim Report January-September 2015
ORION CORPORATION   / INTERIM REPORT / JANUARY-SEPTEMBER 2015 / 27 October 2015 at 12:00 noon EET

OncBioMune Pharmaceuticals Enters Into Common Stock Purchase Agreement With Lincoln Park Capital Fund
BATON ROUGE, LA--(Marketwired - October 26, 2015) - OncBioMune Pharmaceuticals, Inc

Merck and Pfizer Announce Initiation of Phase III First-Line Trial of Avelumab in Patients with Recurrent or Stage IV Non-Small Cell Lung Cancer
Business Wire IndiaNot intended for UK-based media

Takeda Reports Results for the First Half of FY2015Confirms Management Guidance for the Full Year
Business Wire IndiaTakeda Pharmaceutical Company Limited (TOKYO:4502):

Active Biotech's rights issue of approximately SEK 225 million oversubscribed
  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL.

Medigene Receives Clinical Trial Approval for Phase I/II Study with DC Vaccine to Treat Acute Myeloid Leukaemia (AML)
Medigene AG /Medigene Receives Clinical Trial Approval for Phase I/II Study with DC Vaccine to Treat Acute Myeloid Leukaemia (AML) . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Medigene to participate in three international conferences in January
Medigene AG /Medigene to participate in three international conferences in January . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

AIM Applauds AARP's Support of Closing Physician Self-Referral Loophole
FAIRFAX, VA--(Marketwired - December 16, 2014) - The Alliance for Integrity in Medicare (AIM) -- a broad coalition of medical specialty, laboratory, radiation oncology and medical imaging groups committed to ending the practice of inappropriate physician self-referral -- strongly commends the letter sent by the AARP to Rep. Jackie Speier (D-Calif.) on December 11, 2014

Bavarian Nordic Reaches Enrollment Target in the Pivotal Phase 3 Study of PROSTVAC® in Prostate Cancer
KVISTGAARD, Denmark, December 10, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that it has reached the planned enrollment of 1,200 patients in the PROSPECT Phase 3 clinical study of its targeted active immunotherapy candidate, PROSTVAC®, in the treatment of asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer (mCRPC)

Active Biotech's election committee appointed
In accordance with a decision made by the Annual General Meeting held on May 15, 2014, the Election Committee shall comprise the representatives for the three largest shareholders, as per end of September 2014, and the Chairman of the Board.

IsoRay's Cesium-131 Used in World's First Veterinary Implant in a Horse With Cancer
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in brachytherapy and medical isotope applications, today announced the world's first veterinary implant of a horse suffering from cancer utilizing IsoRay's Cesium-131 internal radiation (brachytherapy) cancer therapy.

Prospectus relating to Active Biotech's rights issue published
  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL.

Bavarian Nordic Announces First Subject Dosed with MVA-BN® Filo in a Phase 1 Study Investigating a New Prime-Boost Regimen of Ebola Candidate Vaccines
First human trial investigating MVA-BN® Filo as an Ebola vaccine MVA-BN Filo is being investigated as a booster in an ongoing Phase study 1 of the cAd3-EBO Z vaccine being developed by GSK and the U.S

Over 700,000 Global Movember Participants Raise Funds and Awareness for Prostate Cancer, Testicular Cancer and Mental Health
LOS ANGELES, CA--(Marketwired - December 01, 2014) - The Movember Foundation, the leading global organization committed to changing the face of men's health, has announced the conclusion of the 2014 moustache-growing season, with over 700,000 registered Movember participants worldwide

Extraordinary General Meeting of Active Biotech AB (publ)
  NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL.

Changing the Course of Prostate Cancer Treatment: Life Expectancy Estimation, Active Surveillance, and Drug Development
FORT WASHINGTON, PA--(Marketwired - November 21, 2014) - The National Comprehensive Cancer Network® (NCCN®) has published the 20th annual edition of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer -- one of the eight original NCCN Guidelines® published in November 1996.

Clinical data of Medigene's Dendritic Cell vaccines to be presented at ASH conference
Medigene AG /Clinical data of Medigene's Dendritic Cell vaccines to be presented at ASH conference . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Bavarian Nordic Announces Interim Results for the First Nine Months of 2014
KVISTGAARD, Denmark, November 13, 2014 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) today publishes its interim financial results for the first nine months of 2014.

Initial clinical data on Medigene's DC vaccines to be presented at the SITC Conference
Medigene AG /Initial clinical data on Medigene's DC vaccines to be presented at the SITC Conference . Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

MorphoSys AG Reports Results for the First Nine Months of 2014
MorphoSys AG /MorphoSys AG Reports Results for the First Nine Months of 2014. Processed and transmitted by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the content of this announcement.

Bavarian Nordic to Host Third Quarter 2014 Results Conference Call
KVISTGAARD, Denmark - November 6, 2014 - Bavarian Nordic A/S (OMX:BAVA, OTC: BVNRY) will announce its 2014 third quarter results on Thursday, November 13, 2014.

Active Biotech AB: Notice of Extraordinary General Meeting of Shareholders
The Board of Directors of Active Biotech AB (publ) has issued a notice to an Extraordinary General Meeting, which is to take place at 5 p.m. on Monday, December 1, 2014, at 5 pm at the Company's premises at Scheelevägen 22 in Lund, Sweden.

Active Biotech strengthens its financial position: rights issue of approximately SEK 225 million
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, SINGAPORE, SOUTH AFRICA OR NEW ZEALAND OR IN ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OF THIS PRESS RELEASE WOULD BE UNLAWFUL.

Teva and Active Biotech Announce Expansion of Laquinimod Clinical Development Program with New Trial in Primary Progressive Multiple Sclerosis and First Patient Screened in Huntington's Disease Trial
ARPEGGIO and LEGATO-HD trials will further evaluate the effect of laquinimod in neurodegenerative diseases

Niwali.com Launches Estrodetox
Can the use of marijuana cause man b**bs? According to an article Dr. Anthony Youn, a plastic surgeon from Detroit, wrote for CNN earlier this month, it can. The reason behind it is the drug's effect on hormone levels, causing an imbalance between testosterone and estrogen

Niwali.com Gives Back to Fight Prostate Cancer
Did you notice all the moustaches the guys at your gym suddenly were sporting? Did you think based on the faces of your male neighbors the local Walgreens must have run out of shavers? The revelation of this mystery? November was National Prostate Cancer Awareness Month, also called Movember because millions of men grow mustaches to increase awareness and support ongoing research.

Laquinimod CHMP/EMA Opinion

University of California San Diego and John Muir Medical Center Initiated Treating Patients for Colon and Lung Cancer Utilizing IsoRay's Cesium-131 Seeded Mesh
IsoRay Inc. (NYSE MKT: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it has two new medical centers using its sutured seeds in mesh to treat colon and lung cancers.

Adamis Pharmaceuticals Announces Closing of Public Offering of Common Stock
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the closing of its previously announced underwritten public offering of 3,720,000 shares of common stock at a public offering price of $5.95 per share. The gross proceeds to Adamis from the offering are $22,134,000, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Adamis.

Adamis Pharmaceuticals Announces Pricing of Public Offering of 3,720,000 Shares of Common Stock, Listing on NASDAQ, Reverse Stock Split
Adamis Pharmaceuticals Corporation (NASDAQ: ADMP) today announced the pricing of an underwritten public offering of 3,720,000 shares of common stock at an offering price of $5.95 per share. The gross proceeds to Adamis from this offering are expected to be approximately $22,134,000, before deducting underwriting discounts and commissions and other estimated offering expenses

Movember Salutes More Than Four Million Moustaches Raising Over Half a Billion Dollars Globally for Men's Health
In honor of its milestone tenth moustache season, Movember, the global charity that raises awareness and funds for men's health through the power of the moustache and only a moustache, is proud to announce the closing of an impactful 2013 campaign

Phase II Data on OHR/AVR118 in Advanced Cancer Patients With Cachexia Presented at International Cachexia Conference in Kobe, Japan
Ohr Pharmaceutical (NASDAQ: OHRP), a pharmaceutical company focused on the development of novel therapeutics for large unmet medical needs, announced that full results from a Phase II trial to evaluate the effects of OHR/AVR118 in advanced cancer patients with cachexia were presented yesterday at the 7th International Cachexia Conference in Kobe, Japan

NANOBIOTIX :strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar

Bavarian Nordic Receives Health Canada Approval of IMVAMUNE Smallpox Vaccine
KVISTGAARD, Denmark, November 22, 2013 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) announced today that Health Canada has granted a Notice of Compliance approving IMVAMUNE® for active immunization against smallpox in a public health emergency. IMVAMUNE is indicated for persons 18 years of age and older who are contraindicated to replicating smallpox vaccines

Adamis Pharmaceuticals Announces Proposed Public Offering
Adamis Pharmaceuticals Corporation (OTCQB: ADMP) today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of common stock and warrants. The filing covers up to $25 million in securities

** Health News ** UCLA Urologists Celebrate Movember by Raising Awareness About Prostate and Testicular Cancers
LOS ANGELES, CA--(Marketwired - November 18, 2013) - Mustaches are taking over this month. You'll see them popping up on Facebook, Instagram and Twitter as men from around the country celebrate Movember each November by growing mustaches and raising money for prostate and testicular cancer research, as well as other men's health issues

IsoRay, Inc. Reports First Quarter Results
IsoRay, Inc. (NYSE MKT: ISR) (NYSE Amex: ISR) (http://www.isoray.com/), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of cancers of the brain, lung, head and neck, prostate and gynecological, announced its financial results for the quarter ended September 30, 2013.

Active Biotech's election committee appointed
In accordance with a decision made by the Annual General Meeting held on May 15, 2013, the Election Committee shall comprise the representatives for the three largest shareholders, as per end of September 2013, and the Chairman of the Board.

MagForce AG publishes Shareholder Letter
MagForce AG /MagForce AG publishes Shareholder Letter. Ad hoc announcement according to § 15 WpHG. Processed and transmitted by Thomson Reuters ONE.The issuer is solely responsible for the content of this announcement.

Bavarian Nordic to Host Third Quarter 2013 Results Conference Call
KVISTGAARD, Denmark - November 7, 2013 - Bavarian Nordic A/S (OMX: BAVA, OTC: BVNRY) will announce its 2013 third quarter results on Thursday, November 14, 2013.

Active Biotech's partner Teva initiates a further clinical trial in multiple sclerosis
Lund, Sweden, November 4, 2013 - Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that its partner Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will initiate a further clinical trial, LIBRETTO, to evaluate the efficacy, safety and tolerability of two doses of oral laquinimod (0.6 and 1

Orion Group Interim Report January-September 2013
ORION CORPORATION/ INTERIM REPORT / JANUARY-SEPTEMBER 2013 22 October 2013 at 12:00 noon EEST

Johns Hopkins and Rutgers Medical School Now Utilizing IsoRay's Cesium-131 Sutured Seeds in Treating Metastatic Brain Cancer
IsoRay Inc. (NYSE MKT: ISR) (NYSE Amex: ISR) (www.isoray.com), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced it will host a booth October 21-24th at the Annual Meeting of the Congress of Neurological Surgeons

IsoRay's Cancer Fighting Cesium-131 Seeds, Sutures and Seeded Mesh Receive High Marks With Six Abstracts Presented During (ASTRO) the American Society for Radiation Oncology Conference
IsoRay Inc. (NYSE MKT: ISR) (NYSE Amex: ISR) (http://www.isoray

Eckert & Ziegler BEBIG S.A. Executes Framework Agreement With Leading Russian Radiation Therapy Provider
Seneffe, Belgium, December 31, 2012 - Eckert & Ziegler BEBIG S.A. (Euronext: EZBG; Reuters: EZBG.BR; Bloomberg: EZBG:BB; hereafter "BEBIG") announces the signing of a framework agreement for the local production of brachytherapy devices with ZAO MSM-Medimpex (hereafter "MSM"), a leading Russian distributor of radiation therapy and nuclear medicine equipment

Professor Anthony J. Costello, M.D. Agrees to Conduct Pre-Clinical Testing and Lead the Clinical Trials in Asia and Southeast Asia of Urodyne, Inc. and Hyperdyne, Inc., Subsidiaries Being Created by Trimedyne
TRIMEDYNE, INC. ("Trimedyne") (OTCBB: TMED) today announced Professor Anthony J. Costello, M.D., Head of the Department of Urology of the Royal Melbourne Hospital of the University of Melbourne (Australia), will serve as Lead Investigator in Asia and Southeast Asia, subject to their receiving funding, of the three (3), 300 patient, randomized, controlled clinical trials of Urodyne, Inc

Bavarian Nordic Issues Revised Financial Calendar for 2013
KVISTGAARD, Denmark, December 21, 2012 - Bavarian Nordic A/S (OMX: BAVA) announced today a revised financial calendar for the year 2013. The company has moved the announcement of the 2012 Annual Report from 7 March 2013 to 12 March 2013.

Equity Brief: Ratings Changes for December 20th: SASR, SD, SGY, SLGN, SNSS, ST, STN, TAP
A number of stocks were upgraded and downgraded by equities research analysts today, as reported by Analyst Ratings Network (http://bit.ly/equitybriefdaily) and Equity Brief:

Laquinimod highlights from Teva Investor Day December 11
Lund, Sweden, December 12, 2012 - Active Biotech's (NASDAQ OMX NORDIC: ACTI) partner Teva Pharmaceutical Industries Ltd. hosted yesterday, December 11, 2012, an investor meeting. Teva has a license to develop and commercialize Active Biotech's molecule laquinimod

IsoRay's Cesium-131 Seeds Proves Successful for Brain Cancer Treatment as Presented by Weill Cornell and Barrow Neurological to The Society Of Neuro-Oncology
IsoRay Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications, today announced the presentation of clinical findings at two medical centers of the successful treatment of brain cancers and tumors using IsoRay's patented Cesium-131 (Cs-131) sutured seeds and seed sutured mesh for internal radiation therapy.

Teva Investor Meeting December 11
Lund, Sweden, December 11, 2012 - Active Biotech's (NASDAQ OMX NORDIC: ACTI) partner Teva Pharmaceutical Industries Ltd. will today Tuesday, December 11, 2012 at 12:00 p.m. ET (6:00 p.m. CET) host an investor meeting. Teva has a license to develop and commercialize Active Biotech's molecule laquinimod, and this molecule may be discussed during the meeting

Peregrine Pharmaceuticals Reports Second Quarter Fiscal Year 2013 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a biopharmaceutical company developing first-in-class monoclonal antibodies focused on the treatment and diagnosis of cancer, today announced financial results for the second quarter ended October 31, 2012 of fiscal year (FY) 2013 and provided an update on its advancing clinical pipeline and other corporate developments.

New Roosters Men's Grooming Center Donates to LIVESTRONG
The November 27 grand opening of the new Roosters Men's Grooming Center (MGC) in Cedar Park celebrated milestones and mustaches. The event, held at the shop's 1400 East Whitestone Boulevard location, marked store owner Mike McHenry's first-ever ribbon cutting, and Tony Moline's first as Cedar Park Chamber of Commerce President.

Active Biotech and Ipsen announce completion of recruitment of tasquinimod clinical phase III study in prostate cancer
Active Biotech (NASDAQ OMXNORDIC: ACTI) and Ipsen (Euronext: IPN; ADR: IPSEY) today announced thatthePhase III clinical trial for tasquinimod, a novel compound for thetreatment ofprostate cancer, is successfully enrolled with over 1,200 randomizedpatients asplanned in the clinical protocol. This achievement triggers a EUR10 millionmilestone payment from Ipsen to Active Biotech.

More Than 1.1 Million Moustaches Raise Over $113 Million Globally for Men's Health
Movember, the global charity that raises awareness and funds for men's health, specifically prostate and testicular cancer initiatives, is proud to announce that 208,757 U.S. men and women participated in its sixth annual campaign, raising a remarkable $18 million -- all through the power of the moustache.

Ghent University and MDxHealth Collaborate to Establish a Center in Pharmaco (Epi)genomics
IRVINE, CA, and LIEGE, BELGIUM - November 30, 2012 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today announced that it has joined forces with the Ghent University to establish NXTGNT, a new Center in Pharmaco (Epi)genomics.

MDxHealth announces its delisting from Euronext Amsterdam
IRVINE, CA, and LIEGE, BELGIUM, 29 November 2012 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, currently listed on Euronext Brussels and Euronext Amsterdam, announced today that it will de-list from Euronext Amsterdam effective as of 31 December 2012

Bavarian Nordic Receives Additional Order for IMVAMUNE® Smallpox Vaccines from the Canadian Government

Active Biotech's election committee appointed
In accordance with a decision made by theAnnual General Meeting held on May10, 2012, the Election Committee shall comprise the representatives for thethree largest shareholders, as per end of September 2012, and the Chairmanofthe Board.

Active Biotech's election committee appointed
In accordance with a decision made by the Annual General Meeting held on May 10, 2012, the Election Committee shall comprise the representatives for the three largest shareholders, as per end of September 2012, and the Chairman of the Board.

MDxHealth Provides Third Quarter 2012 Business Update
IRVINE, CA, and LIEGE, BELGIUM, November 15, 2012 - MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to support cancer treatment, today published a business update for the third quarter ending September 30, 2012.

Algeta results for the third quarter 2012
Not intended for US media

IsoRay, Inc. Reports First Quarter Results
IsoRay, Inc. (NYSE MKT: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for brain cancer, lung cancer, head and neck cancer, prostate cancer and gyn cancer announced its financial results for the quarter ended September 30, 2012.

HCG the First Hospital to Introduce FFF Technology in India
HealthCare Global Enterprises Ltd, The Specialist in Cancer Care, is the first cancer care network in India, to introduce Flattening Free Filter Mode technology to treat a patient. This was introduced for the first time in India, for a patient diagnosed with prostate cancer at HCG Cancer Center Ahmedabad. Dr

Judicial Watch Announces Washington's "Ten Most Wanted Corrupt Politicians" for 2011
Judicial Watch, the public interest group that investigates and prosecutes government corruption, today released its 2011 list of Washington's "Ten Most Wanted Corrupt Politicians." The list, in alphabetical order, includes: Rep. Spencer Bachus (R-AL); Former Senator John Ensign (R-NV); Rep. Alcee Hastings (D-FL); Attorney General Eric Holder; Rep. Jesse Jackson, Jr

Prostate Cancer Surgical Outcomes Optimized by Combining Open, Laparoscopic, and Robotic Surgery Methods
A robotic surgical system mishap in Mumbai, India this week caught the attention of prostate cancer specialists and patients worldwide. Due to a rare "hitch" in the robot's functioning, surgery was halted just prior to incision, requiring the team to awaken the patient from anesthesia with his cancerous prostate still intact

INNO-GENE, A WARSAW STOCK EXCHANGE LISTED COMPANY IS THE FIRST IN THE WORLD TO DEVELOP ACCURATE DNA TESTING FOR CANCER AND PLANS TO ENTER THE US MARKET.
PRESS RELEASE

MagForce Signs Letter of Intent with Leading Russian Medical Product Distribution Company Delrus
MagForce AG / MagForce Signs Letter of Intent with Leading Russian Medical ProductDistribution Company Delrus . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement

Prostate HistoScanning(TM): Clinical performance confirmed
The final results of the open phase of the Prostate HistoScanning(TM) European multi-centre clinical study are published. The authors conclude that: "...Prostate HistoScanning(TM) has the potential to benefit the prostate cancer detection and staging pathway with increased cancer detection and tumour localisation...".

Peregrine Pharmaceuticals Reports Second Quarter 2012 Financial Results and Recent Developments
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical-stage biopharmaceutical company developing first-in-class monoclonal antibodies for the treatment of cancer and viral infections, today announced financial results for the second quarter ended October 31, 2011 of fiscal year (FY) 2012 and provided an update on its advancing clinical pipeline and other corporate developments.

National Institutes of Health Suggests Renaming of Low-Risk Prostate Cancer Diagnosis
This week the National Institutes of Health (NIH) fueled ongoing medical debate over the diagnosis and treatment of prostate cancer by suggesting the possibility of removing the label "cancer" from low-risk prostate cancer. Further, the 14-member independent panel favors active monitoring of the disease verses early treatment. For many in the urologic oncology community, including Dr

Frost & Sullivan Lauds BK Medical, Analogic Ultrasound Group for Its Cutting-Edge Advanced Robotic Ultrasound Technology (ART) Solution
Based on its recent analysis of the surgical ultrasound market, Frost & Sullivan recognizes BK Medical, with the 2011 North American Frost & Sullivan Product Differentiation Award for BK Medical's Advanced Robotic Ultrasound Technology (ART™), the industry's first comprehensive solution for integrating surgeon controlled ultrasound into robotic-assisted surgery.

'Defiant' Mugabe says will be "act of cowardice" for him to step down
Zimbabwe's 87-year-old President Robert Mugabe has said that he would not retire ahead of proposed elections next year and would stay on to lead the country against a 'Western campaign for regime change'.

Corporate Social Responsibility Weekly Recap (November 30 – December 7, 2011)
The following releases focus on Corporate Social Responsibility and moved during the week of November 30 – December 7, 2011.

Comment on this story

Share